Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Additional Information:
| Abciximab Biosimilar, Glycoprotein IIb/II Receptor Monoclonal Antibody Recombinant Humanized IgG1 Monoclonal Antibody. |Isotype: Human IgG1 kap|The anti-human Glycoprotein IIb/II receptor monoclonal antibody abciximab biosimilar was produced in mammal cells. |Specificity/Sensitivity: The research grade abciximab biosimilar specifically binds to the human Glycoprotein IIb and II |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade abciximab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab. Abciximab, a glycoprotein IIb/II receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/II inhibitor. While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/II receptor on the platelet membrane. Syd Labs also provides the following research grade antibody biosimilar proteins: Bevacizumab Biosimilar, research grade (VEGF-A) Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli) Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR) Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR) Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Infliximab biosimilar, research grade (TNF alpha) Adalimumab biosimilar, research grade (TNF alpha) Rituximab biosimilar, research grade (CD20) Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF) Palivizumab Biosimilar, research grade (RSV) Omalizumab biosimilar, research grade (IgE) Eculizumab biosimilar, research grade (C5)